Advertisement
"We continue to see strong interest in our SimCell technology," saidJonathan Rennert, President and CEO, BioProcessors Corporation. "Thebiopharmaceutical industry is accelerating its pace to clinical trials inorder to identify successful therapeutic candidates sooner. Expanding ourcapacity and scope allows the company to respond more quickly and effectivelyto this key market need."
Advertisement
A second SimCell System was recently installed as part of an expandedlaboratory and training wing at BioProcessors' Woburn facility. "Two high-throughput Robotic Systems, along with supporting analytical instrumentationand a new multi-media customer training center, provide our new team of cellculture specialists with much more comprehensive applications development andtraining capabilities," added Rennert. "We are now positioned to expandcustomer access to SimCell technology through the introduction of our newSimCell Services."
SimCell Services are customized service offerings tailored to meetspecific cell culture application requirements of BioProcessors' clients.They provide access to SimCell technology through a hosted cell culturedevelopment project, which can range in scope from a simple screeningexperiment to more comprehensive production clone selection, clone stability,media optimization, or process development experiments. SimCell Services helpclients gain better insight into their bioprocesses and reduce developmentrisk by enabling the design of robust, optimized bioprocesses, faster and moreefficiently.
About BioProcessors Corporation
BioProcessors Corporation is a developer and provider of micro-engineeredsolutions for cell culture-based upstream bioprocess development. TheCompany's SimCell technology provides the capability to perform highthroughput cell culture experiments for the development and optimization ofbiopharmaceutical manufacturing processes. The high throughput capability ofthe system enables execution of full and fractional factorial statisticalexperiments at a fraction of the time and cost associated with conventionalscale-down technologies. The result is greater insight and reduced risk forbioprocess development decision making.
For more information on BioProcessors Corporation, contact Eric Denoyer,Marketing Director, BioProcessors Corporation +1 781-305-8867,[email protected], or visit www.bioprocessors.com.
SOURCE BioProcessors Corporation
